New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
INGELHEIM, Germany--(BUSINESS WIRE)--Results from INPULSIS®-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev®......
